drugset
drugset / Trial / NCT02652234

Study of Endostar Subcutaneous Injection in NSCLC

NCT02652234 ↗

Phase 1 Unknown 8 enrolled Jiangsu Simcere Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, single-arm study to assess the safety, tolerability and pharmacokinetics of Endostar subcutaneous injection in Chinese advanced NSCLC patients.

Timeline

Start
2015-08
Primary completion
2016-06
Completion
2016-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Endostar Protein / enzyme biologic — Subcutaneous

Indications

non-small cell lung carcinoma